Abata Therapeutics
Fang Xia has a solid background in the biopharmaceutical industry, starting as a Research Technician at Harvard University in 2009, and progressing to roles at CRISPR Therapeutics, Takeda, and currently at Abata Therapeutics as a Principal Scientist. They have experience in cell therapy process development, CMC, and tech ops, with a focus on research and development in various scientific roles.
Fang Xia attended Harvard University for an unspecified period of time, but the specific degree, field of study, start, and end years are unknown.
Abata Therapeutics
1 followers
Abata Therapeutics is bringing an entirely new approach to the treatment of autoimmune disease by engineering Tregs as targeted therapies that stop immune-mediated destruction, restore homeostasis – a state of harmony – and promote repair in the affected tissues. In addition to their lead program in progressive MS, Abata has early programs in Type 1 Diabetes (T1D) and inclusion body myositis (IBM). They bring together industry experts and deeply engaged pioneers in Treg biology, T cell receptor and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers.